Skip to main content

Patricia Pozo Rosich

.

Institutions of which they are part

Head of group
Headache and Neurological Pain
Vall Hebron Institut de Recerca
Neurology
General Hospital

Patricia Pozo Rosich

Institutions of which they are part

Head of group
Headache and Neurological Pain
Vall Hebron Institut de Recerca
Neurology
General Hospital

.

.

Projects

SENSOMIG IMPACT OF SENSORY AND STRESSFUL STIMULI IN A PRECLINICAL MODEL OF CHRONIC MIGRAINE

IP: Patricia Pozo Rosich
Collaborators: Marta Vila Pueyo
Funding agency: EUROPEAN COMMISSION
Funding: 172932.48
Reference: SENSOMIG_H2020-MSCA-IF2020
Duration: 01/09/2022 - 31/08/2024

A multidisciplinary approach to the identification of BIOmarkers of MIGraine: a proof of concept study based on the stratification of responders CGRP monoclonal Antibodies

IP: Patricia Pozo Rosich
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding:
Reference: EC-ISCIII/ERANET-NEURON/POZO
Duration: 10/10/2019 - 10/10/2019

AhEAD: Algoritmo de predicción de Eficacia de respuesta A tratamiento preventivo en pacientes con migraña crónica: marcaDores biológicos y clínicos

IP: Patricia Pozo Rosich
Collaborators: Alicia Alpuente Ruiz, Eulalia Gine Cipres, Marta Torres Ferrús, Victor José Gallardo Lopez, Edoardo Caronna
Funding agency: Instituto de Salud Carlos III
Funding: 87120
Reference: PI19/01684
Duration: 01/01/2020 - 30/06/2024

BIOMIGA: un abordaje multidisciplinar para la identificacion de biomarcadores en migraña: estudio prueba de concepto basado en la estratificación de respondedores a anticuerpos monoclonales contra el CGRP

IP: Patricia Pozo Rosich
Collaborators: Alicia Alpuente Ruiz, Laila Asskour, Eulalia Gine Cipres, Marta Torres Ferrús, Victor José Gallardo Lopez
Funding agency: Instituto de Salud Carlos III
Funding: 99999.97
Reference: AC19/00124
Duration: 01/01/2020 - 30/06/2024

Related news

Two international studies led by Vall d'Hebron recommend early administration of specific drugs to prevent migraine to achieve a better response to therapy.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

The study, conducted in more than 770 people, concludes that atogepant reduces the frequency of migraine attacks and the need to take medication.

Related professionals

M.Luisa Perez Rodriguez

M.Luisa Perez Rodriguez

Postdoctoral researcher
Donation and transplantation of organs, tissues and cells
Read more
Kalkhoran Siavash Beikoghli

Kalkhoran Siavash Beikoghli

Postdoctoral researcher
Cardiovascular Diseases
Read more
Blanca Grases Pintó

Blanca Grases Pintó

Postdoctoral researcher
Physiology and Pathophysiology of the Digestive Tract
Read more
Iñigo Royo Crespo

Iñigo Royo Crespo

Senior researcher
General Surgery
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.